Ivabradine – a new agent for coronary heart disease treatment

The review is devoted to ivabradine – the first If selective and specific inhibitor, reducing heart rate (HR). It is well known that HR is an independent risk factor, increasing incidence of all-cause, sudden, and cardiovascular death. Ivabradine specifically and dose-dependently binds to f-channels...

Full description

Saved in:
Bibliographic Details
Published inKardiovaskuli͡a︡rnai͡a︡ terapii͡a︡ i profilaktika Vol. 5; no. 3; pp. 88 - 94
Main Authors O. A. Maneshina, S. B. Erofeeva, Yu B. Belousov
Format Journal Article
LanguageRussian
Published SILICEA-POLIGRAF» LLC 01.06.2006
Subjects
if ингибитор
ивабрадин
ишемическая болезнь сердца
смертность
частота сердечных сокращений
Online AccessGet full text

Cover

More Information
Summary:The review is devoted to ivabradine – the first If selective and specific inhibitor, reducing heart rate (HR). It is well known that HR is an independent risk factor, increasing incidence of all-cause, sudden, and cardiovascular death. Ivabradine specifically and dose-dependently binds to f-channels of sinus node cells, inhibits them, and facilitates HR reduction at rest or during maximal physical workload, without affecting mean blood pressure. In three large clinical trials, ivabradine was well-tolerated and demonstrated substantial antianginal and antiischemic effectiveness, at least similar to that for modern antianginal medications – beta-blockers or calcium antagonists. Therefore, ivabradine could be regarded as alternative to modern antianginal medications, in case of contraindications to or adverse effects of standard therapy.
ISSN:1728-8800
2619-0125